Survey reveals 98.9% of US physicians experienced cancer drug shortages in last 12 months

15 November 2012

The Community Oncology Alliance (COA), a US non-profit organization, announced the results of a drug shortage survey of 200 member practices representing 525 physicians across the USA. 98.9% of the respondents reported experiencing a drug shortage in the last year.

Survey participants indicated that the cancer progressed more quickly in more than 60% of patients as a result of the drug shortages, and more than 70% of patients had more severe side effects as a result of drug shortages.

Almost half of those surveyed reported seeing more than one patient per day affected by a drug shortage and 58.2% indicate the shortage in cancer care drugs is increasing. Over 80% of the patients and over 90% of the practices affected by a cancer drug shortage also experienced a more severe financial burden.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics